GJB2 and breast cancer: As differences in the frequency of mammary tumors arose only between Cre- and Cre+ mice treated with DMBA after Cx26 knockout, we decided to further characterize samples from Group 1 to assess whether Cx26 knockout prior to DMBA treatment predisposed the mammary gland to a specific mammary tumour histological subtype.